Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer ...Middle East

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need CHICAGO, April 30, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase...

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer )

Also on site :

• Russia’s international reserves hit all-time high – central bank
• Beloved brand ends controversial 50 cent fee on popular breakfast staple as it gets ahead of Waffle House
• Hamas to deliver final decision on Gaza ceasefire proposal after consultations